Ikerian AG Secures USD 6.18M in Series A Extension to Broaden AI-Driven Healthcare Solutions.
Ikerian AG, specializes in developing AI-driven software solutions to accelerate clinical, research, and pharmaceutical workflows in ophthalmology, optometry, and beyond.
Company Name: Ikerian AG
Location: Bern, Switzerland
Sector: Healthcare AI
Funding Details: Raised USD 6.18M in Series A extension funding, bringing the total to USD 11.66M. The round was led by the corporate venture capital arm of Topcon Healthcare, Inc., with participation from Zürcher Kantonalbank, btov Industrial Technologies fund, managed by Matterwave Ventures, Verve Ventures, and private investors.
Purpose of Investment: To support the continued development and commercial rollout of RetinAI Discovery® in ophthalmology and optometry, and expand into new therapeutic areas such as neurodegenerative disorders, vascular conditions, and rare diseases.
Leadership: Led by CEO Dr. Carlos Ciller.
Product: RetinAI Discovery®, a software solution for medical image and data management and AI in healthcare.
About Company: Ikerian AG, formerly RetinAI Medical AG, with its wholly-owned subsidiary RetinAI U.S., specializes in developing AI-driven software solutions to accelerate clinical, research, and pharmaceutical workflows in ophthalmology, optometry, and beyond.
